跳至主要内容
临床试验/NCT00520819
NCT00520819已完成1 期

Dietary Antioxidant Intervention in Smoking Middle-Aged and Elderly Men

University of Oslo2 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2003年2月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
102
试验地点
2
主要终点
Biomarkers cardiovascular risk including platelet function, lipid levels, inflammation, and markers of endothelial damage.

研究概览

简要总结

The primary objective of this study is to test whether increasing the total intake of antioxidants to middle-aged smoking men increases the antioxidant defence, reduces oxidative damage, and improves biomarkers for oxidative stress.

The secondary objectives is to test whether this strategy improves other cardiovascular risk markers including platelet function, lipid levels, inflammation, and markers of endothelial damage.

详细描述

In this study men smoking 5 or more cigarettes daily will be invited to participate. We will only include individuals with high cardiovascular risk (men rather than women, smokers rather than nonsmokers, middle-aged to elderly rather than young individuals), in order to recruit people with presumed high oxidative stress who might be most likely to show an effect and benefit from our intervention.

at the time of inclusion, participants will be randomized to three groups; control group, kiwi group or phytochemical group. The kiwi group will consume three kiwis a day, whereas the phytochemical group will consume an array of antioxidant-rich food stuffs. The intervention period is eight weeks.

Blood samples will be collected before and after the intervention period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
45 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Men aged 45-75 years
  • Daily smoker of a minimum of 5 cigarettes a day
  • BMI <35 kg/m2 (because of difficulties that may be experienced by morbidly obese individuals in following the diet)
  • Stable weight range of 4 kg or less during the previous 12 weeks

排除标准

  • Any symptomatic CVD (myocardial infarction, angina pectoris, CABG, PCI, CHF, NYHA class III-IV)
  • Diabetes type I or type II taking drugs for diabetes
  • Following a vegetarian diet or near-vegetarian diet currently
  • Allergy to nuts, kiwi fruits, chocolate, strawberries or tomatoes
  • Clinical disorders including gastrointestinal disease impairing compliance with dietary recommendations
  • History of serious or unstable medical or psychiatric disorder
  • Current use of or need of lipid lowering drug treatment, aspirin or non-steroidal anti-inflammatory drugs (NSAID), according to assessment of the primary clinical investigator. Any "over the counter" headache/ pain or cold remedies taken during the study must not contain aspirin or aspirin like drugs such as ibuprofen. These are classed as and will interfere with platelet function, making them unresponsive for a period of 10-14 days. Paracetamol, however, can be taken as an alternative if required
  • History of alcohol/or drug abuse
  • Participation in a drug trial during the previous 30 days
  • Use of drugs (Xenical, Reductil), nutritional supplements or herbs for weight loss within the 4 weeks prior to visit 2 or participation in an active weight reduction program
  • Use of single vitamin or other antioxidants (must be stopped 4 weeks prior to visit 2)
  • Individuals judged by the clinical investigator to be unable to follow instructions and procedures of the study.

结局指标

主要结局

Biomarkers cardiovascular risk including platelet function, lipid levels, inflammation, and markers of endothelial damage.

时间窗: 8 weeks

次要结局

  • Biomarkers cardiovascular risk including platelet function, lipid levels, inflammation, and markers of endothelial damage.(8 weeks)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验